Comparative Study of NXL103 Versus Comparator in Adults With Community Acquired Pneumonia

Sponsor
Novexel Inc (Industry)
Overall Status
Completed
CT.gov ID
NCT00653172
Collaborator
(none)
302
60
3
13
5
0.4

Study Details

Study Description

Brief Summary

The purpose of this study is to compare the efficacy, safety and tolerance of 2 different dose levels of oral NXL103 with oral comparator in the treatment of community acquired pneumonia in adults

Condition or Disease Intervention/Treatment Phase
Phase 2

Study Design

Study Type:
Interventional
Actual Enrollment :
302 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
A Double-Blind, Multicenter, Randomized, Double Dummy, Three-Arm Parallel-Group Comparative Study of the Efficacy, Safety and Tolerance of Oral NXL 103 Versus Oral Comparator in the Treatment of Community-Acquired Pneumonia in Adults
Study Start Date :
Oct 1, 2007
Actual Primary Completion Date :
Jun 1, 2008
Actual Study Completion Date :
Nov 1, 2008

Arms and Interventions

Arm Intervention/Treatment
Experimental: 1

NXL103

Drug: NXL103
500mg orally twice daily

Active Comparator: 3

Drug: comparator
comparator twice daily

Experimental: 2

NXL103

Drug: NXL103
600mg orally twice daily

Outcome Measures

Primary Outcome Measures

  1. Evaluate Clinical outcome [early follow up visit (day 14 to 21)]

Secondary Outcome Measures

  1. Evaluate bacteriological outcome [early follow up visit (day 14 to 21)]

  2. Evaluate safety [first dose, throughout treatment, and to follow up visit]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Community acquired pneumonia
Exclusion Criteria:
  • severe CAP

  • respiratory infections attributed to sources other than community acquired bacterial infection

  • concomitant pulmonary disease

  • history of hypersensitivity to study medication, macrolide or beta lactam antibiotics

Contacts and Locations

Locations

Site City State Country Postal Code
1 Clinica de Enfermedades Resp. "Miguel de Servet" SA Santiago Chile
2 Complejo Asistencial Barros Luco Trudeau Santiago Chile
3 Hospital de Urgencia Asistencia Publica Santiago Chile
4 Hospital Regional de Rancagua Santiago Chile
5 Clinic for infectious diseases Zagreb Croatia
6 General Hospital Sveti Duh Zagreb Croatia
7 University Hospital Dubrava Zagreb Croatia
8 Linnamoisa Perearstikeskus Tallinn Estonia
9 Merelahe Family Doctors Centre Tallinn Estonia
10 Nolvaku Family Doctor Center Tartu Estonia
11 Pullerits & Peda Perearstikeskus Tartu Estonia
12 Marje Toom Family Doctors Practice Voru Estonia
13 Penumologen=Praxis Lichterfelde Berlin Germany
14 Asklepios Klinik St. Georg Hamburg Germany
15 Asklepiosklinik Wandsbeck Hamburg Germany
16 Praxis Dr. H. Mueller Potsdam Germany
17 Praxis Dr. W. Wyborski Werneck Germany
18 Hospital Nacional Arzobispo Loayza Lima Peru
19 Hospital Nacional Guillermo Almenara Lima Peru
20 Indywidualna Specjalistyczna Praktyka Lekarska Bialystok Poland
21 SP ZOZ Wojewodzki Szpital Specjalistyczny im. Bialystok Poland
22 SPZOZ Osrodek Zdrowia wBienkowce Bienkowice Poland
23 NZOZ Poradnia Medycyny Rodzinnej Gdansk Poland
24 Nzoz "Esculap" Gniewkowo Poland
25 Prywatny Gabinet Specjalistyczny Lodz Poland
26 SP ZOZ Wielkopolskie Centrum Chrob Poznan Poland
27 Nzoz "Mig'Med" Wabrzezno Poland
28 Wojewodzki Szpital we wloclawku Wloclawek Poland
29 NZOZ Centrum Badan Klinicznych Wroclaw Poland
30 Spitalul Clinical Judetean de Urgenta Brasov Romania
31 Centrul de Diagnostic si Tratament "Dr. Victor Babes" Bucuresti Romania
32 Spitalul Clinic de Urgenta Bucuresti Bucuresti Romania
33 Spitalul Universitar de Urgenta Bucuresti Bucuresti Romania
34 Spitalul Universitar de Urgenta Elias Bucuresti Romania
35 Dispensarul TB nr. 1 Galati Galati Romania
36 Spitalul de Pneumologie Galati Galati Romania
37 Spitalul Judetean de Urgenta "Sf. loan cel Suceava Romania
38 Centrul Medical Privat "Medicali's" Timosoara Romania
39 Langeberg Medical Centre Cape South Africa
40 GCT Trial Centre, Mercantile Hospital E Cape South Africa
41 Rabie, W Free State South Africa
42 Rubins Building Free State South Africa
43 Benmed Park Clinical Gauteng South Africa
44 Clinresco Centres (Pty) Ltd Gauteng South Africa
45 DJW Navorsing Gauteng South Africa
46 Eastmed Medical Centre Gauteng South Africa
47 Intercare-Medical & Dental Centre Gauteng South Africa
48 Jubilee Hospital Gauteng South Africa
49 Sebastian, P KZ-Natal South Africa
50 Pretoria West Medicross Pretoria West South Africa
51 Clinical Project Research Worcester South Africa
52 DSMA b. on Dnepropetrovsk City Clin. Hosp. #6 Dnepropetrovsk Ukraine
53 DSMU n.a. M. Gorkyy, Don.Reg.Territorial Med. Clin Ass. Donetsk Ukraine
54 Iv-Frank St. Med Uni. b.o.lv Frank. Centr City Clin. Hospital Frankovsk Ukraine
55 Kharkiv City Clinical Hospital # 13 Kharkiv Ukraine
56 City Tuberculosis Hospital # 1 Kiev Ukraine
57 F.G. Yanovskyy Inst. of Ph. & Pulm. of Ac. of Med. Scien. of Ukr Kiev Ukraine
58 F.G. Yanovskyy Institute of P & P AMS of Ukr Kyiv Ukraine
59 Institute of Therapy AMS Ukr. n.a. Malaya Mykolayiv Ukraine
60 Nikolaev City Clinical Hospital # 1 Mykolayiv Ukraine

Sponsors and Collaborators

  • Novexel Inc

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00653172
Other Study ID Numbers:
  • NXL103/2001
First Posted:
Apr 4, 2008
Last Update Posted:
Jan 9, 2009
Last Verified:
Jan 1, 2009
Keywords provided by , ,
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 9, 2009